Curative Biosciences EBITDA vs. Total Debt
| CBDX Stock | USD 0.0001 0.00 0.00% |
For Curative Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Curative Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Curative Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Curative Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Curative Biosciences over time as well as its relative position and ranking within its peers.
Curative |
Curative Biosciences Total Debt vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Curative Biosciences's current stock value. Our valuation model uses many indicators to compare Curative Biosciences value to that of its competitors to determine the firm's financial worth. Curative Biosciences is rated fourth in ebitda category among its peers. It is rated below average in total debt category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Curative Biosciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Curative Biosciences' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Curative Total Debt vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Curative Biosciences |
| = | (50.35 K) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Curative Biosciences |
| = | 156.45 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Curative Total Debt vs Competition
Curative Biosciences is rated below average in total debt category among its peers. Total debt of Drug Manufacturers—Specialty & Generic industry is currently estimated at about 32.29 Million. Curative Biosciences adds roughly 156,450 in total debt claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.
Curative Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Curative Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Curative Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Curative Biosciences' change in net profit over the period of time. It can combine multiple indicators of Curative Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Curative Biosciences, Inc. focuses on developing and commercializing therapeutics using hemp-derived Cannabidiol. Curative Biosciences, Inc. was founded in 2009 and is based in Miami, Florida. Curative Biosciences is traded on OTC Exchange in the United States.
Curative Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Curative Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Curative Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Curative Biosciences' important profitability drivers and their relationship over time.
Use Curative Biosciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Curative Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Curative Biosciences will appreciate offsetting losses from the drop in the long position's value.Curative Biosciences Pair Trading
Curative Biosciences Pair Trading Analysis
The ability to find closely correlated positions to Curative Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Curative Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Curative Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Curative Biosciences to buy it.
The correlation of Curative Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Curative Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Curative Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Curative Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Curative Biosciences position
In addition to having Curative Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Growth Funds Thematic Idea Now
Small Growth Funds
Funds or Etfs that invest in stocks of small to mid-sized companies with above-average risk and growth rate that usually reinvest their earnings back into business. The Small Growth Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Growth Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Curative Pink Sheet Analysis
When running Curative Biosciences' price analysis, check to measure Curative Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biosciences is operating at the current time. Most of Curative Biosciences' value examination focuses on studying past and present price action to predict the probability of Curative Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biosciences' price. Additionally, you may evaluate how the addition of Curative Biosciences to your portfolios can decrease your overall portfolio volatility.